Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
AVITA Medical Sets November 5 Date for Q3 2026 Earnings Report
Highlights:
Earnings Date Confirmed
AVITA Medical, Inc. (ASX: AVH), which develops acute wound-care therapies, said on October 20, 2026 that its third-quarter results will be published on Thursday, November 5, 2026, after the US market close. A conference call and webcast will be held the same day, giving investors and other interested parties a chance to hear management discuss the quarter’s performance and operational progress.
Separately, the company’s shares were last quoted at AU$4.320, a gain of AU$0.330, or 8.27%, according to the market data provided. That move is unrelated to the earnings date announcement.
Call and Webcast Timing
The call is set for 1:30 p.m. Pacific Time on November 5, which is 8:30 a.m. Australian Eastern Daylight Time on Friday, November 6, 2026. Webcast access requires registration through the company’s investor page. Anyone wishing to dial in live must also register beforehand to receive the phone number and a personal PIN.
The company gave no preliminary figures, revenue outlook or guidance ahead of the release, and it did not say which metrics or product updates would be covered.
A Portfolio Built Around Wound Healing
AVITA Medical develops technologies intended to speed wound recovery and improve patient outcomes. Its lead product, RECELL, turns a small sample of a patient’s own skin into a Spray-On Skin preparation for treating thermal burns and trauma wounds, and it holds US FDA approval for these uses. The company also has exclusive US commercial rights to Cohealyx, a collagen-based dermal matrix, as well as rights to manufacture and sell PermeaDerm, a biosynthetic wound matrix.
Outside the US, RECELL and RECELL GO hold clearances or approvals in multiple regions, including Europe, Australia and New Zealand, and RECELL is also approved in Japan.
Outlook
With results due November 5 (November 6 in Australia), investors will be looking for updates on financial performance and progress across AVITA Medical’s wound-care offerings.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au